A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- Takeda
- Azonosító
- NCT06677892
- A regiszteradat frissítve
- 2026. november 12.
- Eredeti leírás
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.A teljes eredeti leírásKevesebb
Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection/Disease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.
The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria.
During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Bevonási feltételek: Participant signed an informed consent form; Aged greater than or equal to (>=) 18 years at the time of consent; Received an HSCT/SOT; Diagnosed with CMV infection/disease any time after the HSCT/SOT date; Starting maribavir for the first time and in line with the Belgian reimbursement criteria.
Kizáró feltételek: Participant treated with maribavir before the start of the study.